IMRX

Immuneering Corporation

IMRX · CIK 1790340 · Annual (10-K) · Last 4 years

Financial Trends

Revenue
20212024
Net Income−$61M
20212024
Operating CF−$55M
20212024
Free Cash Flow−$55M
20212024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue—$0.0B$0.0B$0.0B
Cost of Revenue—$0.0B$0.0B$0.0B
Gross Profit—$0.0B$0.0B$0.0B
R&D Expense$0.0B$0.0B$0.0B$0.0B
SG&A Expense————
Operating Income$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-2.04$-1.88$-1.91$-2.46
EPS (Diluted)$-2.04$-1.88$-1.90$-2.46

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.1B$0.1B$0.1B$0.2B
Current Assets$0.0B$0.1B$0.1B$0.2B
Cash & Equivalents$0.0B$0.1B$0.1B$0.1B
Total Liabilities$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.1B$0.1B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.1B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$0.0B$0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.1B
← Companies